Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) — BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced that Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, has been selected as “Overall Cell Biology Company of the Year” in the third annual BioTech Breakthrough Awards program.
Garuda earned the BioTech Breakthrough Award for the company’s efforts to create off-the-shelf, hematopoietic stem cell (HSC) therapies with the aim of eliminating the dependency on donor or patient cells for blood stem cell transplants entirely. As the industry’s first off-the-shelf offering, Garuda’s unique technology for generating self-renewing blood stem cells provides the company with the ability to manufacture at scale and provide potentially curative therapies for more than 120 diseases, at a fraction of the cost.
“Garuda is working tirelessly to bring our off-the-shelf durable blood stem cell and immune cell programs to millions of patients in need of curative treatments,” said Dhvanit Shah, Ph.D., Co-Founder and CEO of Garuda. “We’re thrilled to see our efforts to advance durable, cost-effective and scalable medicines recognized by BioTech Breakthrough, and are honored to have been selected as ‘Overall Cell Biology Company of the Year.’”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,500 nominations from over 12 different countries.
“Garuda’s technology for generating self-renewing blood stem cells has the potential to revolutionize the hematopoietic stem cell transplant practice and bypass many of the challenges associated with existing treatments,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “We’re pleased to recognize Garuda as ‘Overall Cell Biology Company of the Year,’ and we look forward to seeing Garuda’s continued progress as the Company works to deliver life-changing cellular therapeutics to patients.”
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
About Garuda Therapeutics
Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com/
Media Contact:
Bryan Vaughn
BioTech Breakthrough
Bryan@BioTechBreakThroughAwards.com
949.529.4120
- Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate - May 12, 2025
- Lead Service Line Replacement Cost Calculator (LSLRCC) Federal Trademark and Copyright Applications Filed by Environmental & Public Health International - May 12, 2025
- PageUp Unifies Brands to Strengthen Market Leadership and Enhance Customer Experience - May 12, 2025
